OMS 721

Drug Profile

OMS 721

Alternative Names: anti-MASP-2 monoclonal antibody; MASP-2 therapeutic; OMS-721

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Omeros Corporation
  • Class Anti-inflammatories; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action MASP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic microangiopathies
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Haemolytic uraemic syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemolytic uraemic syndrome
  • Phase II Glomerulonephritis; IgA nephropathy; Lupus nephritis; Membranous glomerulonephritis; Thrombotic microangiopathies
  • Preclinical Stroke; Wet age-related macular degeneration

Most Recent Events

  • 06 Dec 2016 Efficacy data from a compassionate use programme in Thrombotic microangiopathies released by Omeros
  • 03 Nov 2016 Omeros Corporation files for Orphan drug designation of OMS 721 with the FDA for treatment of patients with IgA nephropathy in USA
  • 03 Nov 2016 Omeros Corporation plans phase III trials for Haematopoietic stem cell transplant (HSCT)-related Thrombotic microangiopathies and IgA nephropathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top